Risankizumab is a medication used in this trial to treat adults with moderate plaque psoriasis. It works by targeting specific proteins in the immune system that contribute to the inflammation and skin symptoms associated with psoriasis. The trial aims to show that risankizumab is more effective than another treatment in reducing the severity of psoriasis symptoms.

Deucravacitinib is another medication being tested in this trial for the treatment of moderate plaque psoriasis in adults. It functions by inhibiting certain enzymes that play a role in the immune response, which can help reduce the inflammation and skin lesions seen in psoriasis. The trial compares the effectiveness of deucravacitinib with risankizumab to determine which is more beneficial for patients.

Plaque Psoriasis – Plaque psoriasis is a chronic autoimmune condition that primarily affects the skin, leading to the development of thick, red, scaly patches known as plaques. These plaques are often itchy and can appear anywhere on the body, but are most commonly found on the elbows, knees, scalp, and lower back. The condition occurs when the immune system mistakenly attacks healthy skin cells, causing them to multiply rapidly. This results in the buildup of skin cells on the surface, forming the characteristic plaques. The severity of plaque psoriasis can vary, with some individuals experiencing only minor patches, while others may have extensive coverage. The disease often goes through cycles, with periods of flare-ups followed by times of remission.